Originally published as JCO Early Release 10.1200/JCO.2003.11.138 on February 7 2003

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hirschfeld, S. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Hirschfeld, S. Articles by Pazdur, R. Social Bookmarking                            What's this?

Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives

From the Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; and GlaxoSmithKline, Philadelphia, PA

Address reprint requests to Steven Hirschfeld, MD, PhD, Division of Oncology Drug Products, Center for Drug Evaluation and Research, HFD-150, Food and Drug Administration, 1451 Rockville Pike, Rockville, MD 20852; email: hirschfelds{at}cder.fda.gov.

Purpose: To review the Food and Drug Administration (FDA) experience with approvals of new drugs for pediatric oncology and to discuss new regulatory initiatives directed at pediatric oncology.

Methods: A retrospective review of FDA archival documents and the published literature.

Results: More than 100 drugs have been approved by the Division of Oncology Drug Products of the FDA for the treatment of malignancies. Only 15 have pediatric use information in their labeling, which is less than 50% of the drugs commonly used in the treatment of pediatric malignancies. In the past 20 years, there have been six submissions to the FDA for pediatric oncology indications. To illustrate principles of the approval process, each submission is discussed.

Conclusion: Potential reasons for a lack of New Drug Application submissions for pediatric oncology include the small pediatric oncology market compared with the adult oncology market and perceived barriers to performing studies in children. Reasons for failure to approve pediatric indications include small numbers of patients, lack of appropriate controls, and failure to demonstrate patient benefit. Approval criteria include the use of controlled trials, prospective data collection, and disease-appropriate end points. Regulatory initiatives to promote pediatric therapeutic development and product labeling are discussed.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. C. Huszthy, D. Goplen, F. Thorsen, H. Immervoll, J. Wang, A. Gutermann, H. Miletic, and R. Bjerkvig Oncolytic Herpes Simplex Virus Type-1 Therapy in a Highly Infiltrative Animal Model of Human Glioblastoma Clin. Cancer Res., March 1, 2008; 14(5): 1571 - 1580. [Abstract] [Full Text] [PDF]

				A. M. Sonabend, I. V. Ulasov, M. A. Tyler, A. A. Rivera, J. M. Mathis, and M. S. Lesniak Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma Stem Cells, March 1, 2008; 26(3): 831 - 841. [Abstract] [Full Text] [PDF]

				Y. Wu, X. Lun, H. Zhou, L. Wang, B. Sun, J. C. Bell, J. W. Barrett, G. McFadden, J. A. Biegel, D. L. Senger, et al. Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1218 - 1227. [Abstract] [Full Text] [PDF]

				S. Hirschfeld Credibility Threshold: Making Efficacy Study Data Generalizable ASCO Educational Book, January 1, 2008; 2008(1): 108 - 111. [Abstract] [Full Text] [PDF]

				M. Candolfi, G. E. Pluhar, K. Kroeger, M. Puntel, J. Curtin, C. Barcia, A.K.M. G. Muhammad, W. Xiong, C. Liu, S. Mondkar, et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro Neuro-oncol, July 1, 2007; 9(3): 245 - 258. [Abstract] [Full Text] [PDF]

				D. Bourbeau, C. J. Lau, J. Jaime, Z. Koty, S. P. Zehntner, G. Lavoie, A.-M. Mes-Masson, J. Nalbantoglu, and B. Massie Improvement of Antitumor Activity by Gene Amplification with a Replicating but Nondisseminating Adenovirus Cancer Res., April 1, 2007; 67(7): 3387 - 3395. [Abstract] [Full Text] [PDF]

				X. Lun, D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, et al. Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas. J Natl Cancer Inst, November 1, 2006; 98(21): 1546 - 1557. [Abstract] [Full Text] [PDF]

				M. ter Horst, S. M. Verwijnen, E. Brouwer, R. C. Hoeben, M. de Jong, B. H.C.G.M. de Leeuw, and P. A.E. Sillevis Smitt Locoregional Delivery of Adenoviral Vectors J. Nucl. Med., September 1, 2006; 47(9): 1483 - 1489. [Abstract] [Full Text] [PDF]

				M. A. Tyler, I. V. Ulasov, A. Borovjagin, A. M. Sonabend, A. Khramtsov, Y. Han, P. Dent, P. B. Fisher, D. T. Curiel, and M. S. Lesniak Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol. Cancer Ther., September 1, 2006; 5(9): 2408 - 2416. [Abstract] [Full Text] [PDF]

				J. Boklan Little patients, losing patience: pediatric cancer drug development. Mol. Cancer Ther., August 1, 2006; 5(8): 1905 - 1908. [Full Text] [PDF]

				A. W. Tolcher, D. Hao, J. de Bono, A. Miller, A. Patnaik, L. A. Hammond, L. Smetzer, J. Van Wart Hood, J. Merritt, E. K. Rowinsky, et al. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2052 - 2058. [Abstract] [Full Text] [PDF]

				S. Jeha, P. S. Gaynon, B. I. Razzouk, J. Franklin, R. Kadota, V. Shen, L. Luchtman-Jones, M. Rytting, L. R. Bomgaars, S. Rheingold, et al. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia J. Clin. Oncol., April 20, 2006; 24(12): 1917 - 1923. [Abstract] [Full Text] [PDF]

				T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]

				A. Nakamizo, F. Marini, T. Amano, A. Khan, M. Studeny, J. Gumin, J. Chen, S. Hentschel, G. Vecil, J. Dembinski, et al. Human Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Gliomas Cancer Res., April 15, 2005; 65(8): 3307 - 3318. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, et al. Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma Clin. Cancer Res., February 15, 2005; 11(4): 1512 - 1520. [Abstract] [Full Text] [PDF]

				S M Selkirk Gene therapy in clinical medicine Postgrad. Med. J., October 1, 2004; 80(948): 560 - 570. [Abstract] [Full Text] [PDF]

				B. Geoerger, G. Vassal, P. Opolon, C. M. F. Dirven, J. Morizet, L. Laudani, J. Grill, G. Giaccone, W. P. Vandertop, W. R. Gerritsen, et al. Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Ad{Delta}24-p53 against Human Malignant Glioma Cancer Res., August 15, 2004; 64(16): 5753 - 5759. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]

				F. Schlachetzki, Y. Zhang, R. J. Boado, and W. M. Pardridge Gene therapy of the brain: The trans-vascular approach Neurology, April 27, 2004; 62(8): 1275 - 1281. [Abstract] [Full Text] [PDF]

				R. J. Weil Potential Confounding Features in p53 Gene Therapy of Recurrent Glioma J. Clin. Oncol., April 1, 2004; 22(7): 1344 - 1345. [Full Text] [PDF]

				F. F. Lang and W.K. Alfred Yung In Reply: J. Clin. Oncol., April 1, 2004; 22(7): 1345 - 1345. [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]